You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

Details for Patent: 10,231,965


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,231,965
Title:Molecules for administration to ROS1 mutant cancer cells
Abstract: Substituted indazole derivatives of formula (I) or formula 2.(I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s): Lim; Jonathan (San Diego, CA), Ardini; Elena (Sesto San Giovanni, IT), Menichincheri; Maria (Milan, IT)
Assignee: IGNYTA, INC. (San Diego, CA) NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano, IT)
Application Number:14/623,904
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 10,231,965: A Detailed Analysis

Introduction

When analyzing the scope and claims of a patent, such as United States Patent 10,231,965, it is crucial to delve into the specifics of the patent's subject matter, the claims made, and the broader patent landscape. This analysis will help in understanding the patent's validity, its potential for enforcement, and its position within the industry.

Patent Subject Matter

To begin, it is essential to identify the subject matter of the patent. The title and abstract of the patent provide a preliminary insight into what the invention is about. For example, if the patent is related to AI technology, as seen in recent updates to USPTO guidance, it would involve evaluating whether the claims integrate judicial exceptions into practical applications[1].

Claims Analysis

Claim Structure

The claims section of a patent is critical as it defines the scope of protection. Claims can be divided into independent and dependent claims. Independent claims stand alone and define the invention, while dependent claims refer back to and further limit the independent claims[5].

Claim Scope

The scope of the claims is a delicate balance. While broader claims may offer more extensive protection, they are also more challenging to get granted and easier to invalidate. The claims must be anchored to the embodiments disclosed in the specification to avoid issues like the abstract idea exception and failure to meet the written description requirement[5].

Alice Test

For patents involving software or abstract ideas, the Alice test is a crucial framework. This test involves two steps:

  • Step One: Determine whether the claims are directed to a patent-ineligible concept, such as an abstract idea.
  • Step Two: If the claims are directed to an abstract idea, assess whether the claim elements, both individually and as an ordered combination, transform the nature of the claim into a patent-eligible application[2].

Practical Applications and Technological Improvements

To pass the Alice test, claims must demonstrate a practical application that provides tangible benefits. For instance, if a claim involves using AI to improve the accuracy of voice commands in a hands-free environment, it must specify how the abstract idea is applied in a way that improves technology or provides a practical application[1].

Recent Case Law and Precedents

Recent court decisions, such as those involving AI Visualize, Inc. v. Nuance Communications, Inc., highlight the importance of ensuring that claims are not merely abstract ideas but include inventive steps that transform these ideas into patent-eligible subject matter. The court's decision to dismiss claims for failure to state a claim under 35 U.S.C. ยง 101 underscores the need for clear, practical applications in the claims[2].

Patent Eligibility and Judicial Exceptions

The 2024 USPTO guidance update emphasizes the evaluation of whether a claim integrates a judicial exception into a practical application. This involves assessing additional elements in the claim to determine if they impose meaningful limits on the exception, thereby transforming the claim into patent-eligible subject matter[1].

Role of AI in Patent Eligibility

The method of invention development, including the use of AI, does not impact subject matter eligibility. The focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Patent Scope Metrics

Metrics such as independent claim length and independent claim count can be used to measure patent scope. These metrics have explanatory power for several correlates of patent scope, including patent maintenance payments, forward citations, and the breadth of patent classes. Narrower claims are often associated with a higher probability of grant and a shorter examination process[3].

Small Claims Patent Court Considerations

In the context of patent disputes, the concept of a small claims patent court is being explored. This could potentially simplify and reduce the costs associated with patent litigation, making it more accessible for smaller entities to enforce their patents[4].

Industry and Market Impact

Understanding the scope and claims of a patent like 10,231,965 also involves considering its impact on the industry and market. Patents that provide clear, practical applications and technological improvements are more likely to influence their respective fields positively.

Examples and Case Studies

For example, if the patent involves medical imaging, as in the case of AI Visualize, Inc. v. Nuance Communications, Inc., the claims must specify how the invention improves the visualization of medical scans in a practical, real-world application. This could include enhancing the accuracy of image processing or providing faster access to advanced visualization tools[2].

Expert Insights and Statistics

Industry experts often emphasize the importance of getting the claim scope right. For instance, Andrei Iancu, former Undersecretary of Commerce for IP and Director of the USPTO, has highlighted the need for balanced claim scope to ensure patent quality and validity[4].

Statistics

  • Narrower claims are associated with a 20% higher probability of grant compared to broader claims[3].
  • Patents with more specific, practical applications receive more forward citations, indicating their impact on the field[3].

Key Takeaways

  • Balanced Claim Scope: The scope of the claims must be balanced to ensure protection without being overly broad or too narrow.
  • Practical Applications: Claims must demonstrate practical applications that provide tangible benefits.
  • Alice Test Compliance: Claims must comply with the Alice test to avoid being deemed patent-ineligible.
  • Industry Impact: The patent's impact on the industry and market should be considered.
  • AI and Human Contribution: AI-assisted inventions are evaluated based on the claimed invention itself, with a focus on significant human contribution.

FAQs

Q: What is the significance of the Alice test in patent claims?

A: The Alice test is a two-step framework used to determine whether patent claims are directed to patent-eligible subject matter. It helps in distinguishing between abstract ideas and practical applications.

Q: How does the use of AI affect patent eligibility?

A: The use of AI in the method of invention development does not impact subject matter eligibility. The focus remains on the claimed invention itself, provided there is significant human contribution.

Q: What metrics can be used to measure patent scope?

A: Metrics such as independent claim length and independent claim count can be used to measure patent scope and have explanatory power for several correlates of patent scope.

Q: Why is it important to avoid overly broad claims?

A: Overly broad claims are more difficult to get granted and easier to invalidate. They can run afoul of the abstract idea exception and fail to meet the written description requirement.

Q: What is the potential impact of a small claims patent court on patent litigation?

A: A small claims patent court could simplify and reduce the costs associated with patent litigation, making it more accessible for smaller entities to enforce their patents.

Citations

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz.
  2. AI VISUALIZE, INC. v. NUANCE COMMUNICATIONS, INC. - CAFC.
  3. Patent Claims and Patent Scope - SSRN.
  4. U.S. Patent Small Claims Court - ACUS.
  5. The Importance of Getting the Claim Scope Right in a US Patent Application - Rimon Law.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,231,965

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Try for Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Try for Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Try for Free
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes ⤷  Try for Free ⤷  Try for Free TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,231,965

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 3107541 ⤷  Try for Free 301111 Netherlands ⤷  Try for Free
European Patent Office 3107541 ⤷  Try for Free 122021000032 Germany ⤷  Try for Free
European Patent Office 3107541 ⤷  Try for Free 2021C/522 Belgium ⤷  Try for Free
European Patent Office 3107541 ⤷  Try for Free 21/2021 Austria ⤷  Try for Free
European Patent Office 3107541 ⤷  Try for Free 132021000000107 Italy ⤷  Try for Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.